[go: up one dir, main page]

PE20130382A1 - Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a - Google Patents

Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a

Info

Publication number
PE20130382A1
PE20130382A1 PE2012001636A PE2012001636A PE20130382A1 PE 20130382 A1 PE20130382 A1 PE 20130382A1 PE 2012001636 A PE2012001636 A PE 2012001636A PE 2012001636 A PE2012001636 A PE 2012001636A PE 20130382 A1 PE20130382 A1 PE 20130382A1
Authority
PE
Peru
Prior art keywords
amide
lower alkyl
imidazopyrimidin
heteroarylamide
pde10a
Prior art date
Application number
PE2012001636A
Other languages
English (en)
Inventor
Sanchez Ruben Alvarez
Konrad Bleicher
Alexander Flohr
Luca Gobbi
Katrin Groebke Zbinden
Mathias Koerner
Bernd Kuhn
Jens-Uwe Peters
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20130382A1 publication Critical patent/PE20130382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE N-(IMIDAZOPIRIMIDIN-7-IL)-HETEROARILAMIDA DE FORMULA (I) DONDE R1 ES FENILO O TIENILO OPCIONALMENTE SUSTUIDO CON OH, HALOGENO, ALQUILO INFERIOR, ENTRE OTROS; R2 ES UN HETEROARILO MONOCICLICO DE 5 O 6 ESLABONES QUE TIENE DE 1 A 3 HETEROATOMOS OPCIONALMENTE SUSTITUIDO CON NITRO, ALQUILO INFERIOR, ALCOXI INFERIOR, ENTRE OTROS; R8 ES HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[(2-FLUOR-ETIL)-METIL-AMIDA]3-{[2-(3-FLUORMETOXIFENIL)-IMIDAZOL[1,2-a]PIRIMIDIN-7-IL]-AMIDA}DEL ACIDO 2-METIL-2H-PIRAZOL-3,4-DICARBOXILICO, 2-[(2-FENIL-IMIDAZO[1,2-a]PIRIMIDIN-7-IL)-AMIDA] 3-[(2,2,2-TRIFLUOR-ETIL)-AMIDA] DEL ACIDO PIRAZINA-2,3- DICARBOXILICO, ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA 10A (PDE10A) SIENDO UTILES PARA EL TRATAMIENTO TERAPEUTICO Y/O PROFILACTICO DE LOS TRANSTORNOS PSICOTICOS, LA ESQUIZOFRENIA, TRANSTORNO DE LA ALUCINACION ENTRE OTROS.
PE2012001636A 2010-03-26 2011-03-23 Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a PE20130382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10158011 2010-03-26

Publications (1)

Publication Number Publication Date
PE20130382A1 true PE20130382A1 (es) 2013-03-30

Family

ID=43989818

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001636A PE20130382A1 (es) 2010-03-26 2011-03-23 Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a

Country Status (26)

Country Link
US (1) US8410117B2 (es)
EP (1) EP2552918B1 (es)
JP (1) JP5764196B2 (es)
KR (1) KR20130073876A (es)
CN (1) CN102791714B (es)
AR (1) AR080785A1 (es)
AU (1) AU2011231668A1 (es)
BR (1) BR112012024199A2 (es)
CA (1) CA2786213A1 (es)
CL (1) CL2012002497A1 (es)
CR (1) CR20120443A (es)
EC (1) ECSP12012174A (es)
ES (1) ES2478448T3 (es)
HK (1) HK1173440A1 (es)
IL (1) IL220932A0 (es)
MA (1) MA34069B1 (es)
MX (1) MX2012010880A (es)
NZ (1) NZ600927A (es)
PE (1) PE20130382A1 (es)
PH (1) PH12012501772A1 (es)
RU (1) RU2562066C2 (es)
SG (1) SG183824A1 (es)
TW (1) TWI478924B (es)
UA (1) UA108640C2 (es)
WO (1) WO2011117264A1 (es)
ZA (1) ZA201206257B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
AU2012325916A1 (en) * 2011-10-20 2014-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
BR112014009518A2 (pt) * 2011-10-20 2017-04-25 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores da sirtuína
BR112015002779A2 (pt) * 2012-08-17 2019-10-15 Hoffmann La Roche processo para a preparação de derivados de ácido carboxílico de pirazol
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2603931T3 (es) * 2012-11-07 2017-03-02 F. Hoffmann-La Roche Ag Compuestos de triazolo
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
ES2723876T3 (es) * 2013-02-27 2019-09-03 Mochida Pharm Co Ltd Nuevos derivados de pirazol
AU2014270524B2 (en) * 2013-05-23 2018-01-04 F. Hoffmann-La Roche Ag 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
KR101770532B1 (ko) * 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
PL408251A1 (pl) 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MY199220A (en) 2015-11-19 2023-10-20 Incyte Corp Heterocyclic compounds as immunomodulators
BR112018012756A2 (pt) 2015-12-22 2018-12-04 Incyte Corp compostos heterocíclicos como imunomoduladores
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
SG10202012828TA (en) 2016-06-20 2021-01-28 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3558990T (pt) 2016-12-22 2022-11-21 Incyte Corp Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
MX2022003578A (es) 2019-09-30 2022-05-30 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
WO2021080312A1 (ko) * 2019-10-21 2021-04-29 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8106502A1 (es) 1980-07-17 1981-07-01 Consejo Superior Investigacion Procedimiento para la preparacion de 3(6 5)-formilpira- zol-4-carboxilatos de alquilo
DE60018037T2 (de) * 1999-11-10 2006-01-12 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren
CA2410037C (en) 2000-05-24 2009-11-03 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
BRPI0412636A (pt) * 2003-07-30 2006-09-26 S A L V A T Lab Sa imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
RU2426732C2 (ru) * 2006-01-17 2011-08-20 Ф. Хоффманн-Ля Рош Аг АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1,2-a]ПИРИДИН, ПРИГОДНЫЙ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА ЧЕРЕЗ ПОСРЕДСТВО GABA-РЕЦЕПТОРОВ
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
EP1964841A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
DE102007048716A1 (de) * 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
EP2552918A1 (en) 2013-02-06
RU2012143794A (ru) 2014-05-10
AU2011231668A1 (en) 2012-07-19
PH12012501772A1 (en) 2017-07-26
MX2012010880A (es) 2012-10-15
HK1173440A1 (en) 2013-05-16
US20110237564A1 (en) 2011-09-29
ZA201206257B (en) 2013-05-29
CN102791714B (zh) 2015-03-25
MA34069B1 (fr) 2013-03-05
AR080785A1 (es) 2012-05-09
ES2478448T3 (es) 2014-07-22
CR20120443A (es) 2012-10-11
IL220932A0 (en) 2012-09-24
NZ600927A (en) 2013-08-30
SG183824A1 (en) 2012-10-30
CN102791714A (zh) 2012-11-21
UA108640C2 (uk) 2015-05-25
US8410117B2 (en) 2013-04-02
JP2013523673A (ja) 2013-06-17
WO2011117264A1 (en) 2011-09-29
JP5764196B2 (ja) 2015-08-12
TW201136937A (en) 2011-11-01
CL2012002497A1 (es) 2013-03-22
CA2786213A1 (en) 2011-09-29
RU2562066C2 (ru) 2015-09-10
TWI478924B (zh) 2015-04-01
ECSP12012174A (es) 2012-10-30
EP2552918B1 (en) 2014-06-11
KR20130073876A (ko) 2013-07-03
BR112012024199A2 (pt) 2016-07-05

Similar Documents

Publication Publication Date Title
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20190913A1 (es) Derivados aromaticos de sulfonamida
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20140934A1 (es) Derivados de pirazol
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
PE20140927A1 (es) Compuestos heterociclicos como inhibidores de cinasas
CO6390057A2 (es) Indazoles oxazol sustituidos como inhibidores de pi3-quinasa
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
PE20130155A1 (es) Derivados de ariletinilo
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk

Legal Events

Date Code Title Description
FA Abandonment or withdrawal